"Scientists have produced an infant ‘chimeric’ monkey by injecting a monkey embryo with stem cells from a genetically distinct donor embryo1. The resulting animal is the first live-born chimeric primate to have a high proportion of cells originating from donor stem cells."
https://www.nature.com/articles/d41586-023-03473-w
https://www.nature.com/articles/d41586-023-03473-w
Nature
This hybrid baby monkey is made of cells from two embryos
Nature - The monkey’s creation paves the way for scientists to use chimaeric primates to study human diseases.
The first real antiaging drug has just received FDA approval:
"Today, I’m so proud to announce that Loyal has earned what we believe to be the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan. In regulatory parlance, we have completed the technical effectiveness portion of our conditional approval application for LOY-001’s use in large dog lifespan extension.
As there was no established regulatory path for a lifespan extension drug, we had to design from scratch a scientifically strong and logistically feasible way to demonstrate efficacy of an aging drug. This process took more than four years, resulting in the 2,300+ page technical section now approved by the FDA. It included interventional studies of LOY-001 in an FDA-accepted model of canine aging and an observational (no-drug) study of 451 dogs.
Our interventional studies with LOY-001 showed that the drug improved clinically-relevant aging parameters. We assessed these in laboratory studies using a dog model that represents accelerated aging. We then correlated those results with quality of life scores in the observational study, as independently measured by dog owners, and health outcomes as measured by veterinarians. This was key to show that the biological benefits of the drug are linked to clinically relevant outcomes.
From our data, the FDA believes LOY-001 is likely to be effective for large dog lifespan extension in the real world. Once we satisfactorily complete safety and manufacturing sections and other requirements, vets will be able to prescribe LOY-001 to extend the lifespan of large dogs while we complete the confirmatory pivotal lifespan extension study in parallel."
~ Celine Halioua, founder of Loyal
"Today, I’m so proud to announce that Loyal has earned what we believe to be the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan. In regulatory parlance, we have completed the technical effectiveness portion of our conditional approval application for LOY-001’s use in large dog lifespan extension.
As there was no established regulatory path for a lifespan extension drug, we had to design from scratch a scientifically strong and logistically feasible way to demonstrate efficacy of an aging drug. This process took more than four years, resulting in the 2,300+ page technical section now approved by the FDA. It included interventional studies of LOY-001 in an FDA-accepted model of canine aging and an observational (no-drug) study of 451 dogs.
Our interventional studies with LOY-001 showed that the drug improved clinically-relevant aging parameters. We assessed these in laboratory studies using a dog model that represents accelerated aging. We then correlated those results with quality of life scores in the observational study, as independently measured by dog owners, and health outcomes as measured by veterinarians. This was key to show that the biological benefits of the drug are linked to clinically relevant outcomes.
From our data, the FDA believes LOY-001 is likely to be effective for large dog lifespan extension in the real world. Once we satisfactorily complete safety and manufacturing sections and other requirements, vets will be able to prescribe LOY-001 to extend the lifespan of large dogs while we complete the confirmatory pivotal lifespan extension study in parallel."
~ Celine Halioua, founder of Loyal
Loyal Blog
FDA Center for Veterinary Medicine agrees Loyal’s data supports reasonable expectation of effectiveness for large dog lifespan…
A historic milestone in developing the first drug for healthy lifespan extension in dogs
https://youtube.com/shorts/VEhfOWo7VfU?si=-NxQm2CkNXHOBHbI
There is a point in Sinclair's speech that is worrying, he says: can the restart or rejuvenation be done perhaps hundreds of times, which implies a limit or attrition? of the information? Isn't it supposed that if it is done it should be able to be done without limits?
There is a point in Sinclair's speech that is worrying, he says: can the restart or rejuvenation be done perhaps hundreds of times, which implies a limit or attrition? of the information? Isn't it supposed that if it is done it should be able to be done without limits?
YouTube
A REVERSE AGING PILL May Only Cost A Few Cents @Day!!! | Dr David Sinclair #shorts
Dr. David Sinclair talks about how reverse aging in a pill may work and aim to make the cost of reverse aging treatment as low as possible in this clip.https...